The DOI matches its Crossref record; 78 of the 81 references it cites were found in a registry or an index.
A Kinase-Independent Function of CDK6 Links the Cell Cycle to Tumor Angiogenesis
Open accessAbstract
In contrast to its close homolog CDK4, the cell cycle kinase CDK6 is expressed at high levels in lymphoid malignancies. In a model for p185BCR-ABL+ B-acute lymphoid leukemia, we show that CDK6 is part of a transcription complex that induces the expression of the tumor suppressor p16INK4a and the pro-angiogenic factor VEGF-A. This function is independent of CDK6's kinase activity. High CDK6 expression thus suppresses proliferation by upregulating p16INK4a, providing an internal safeguard. However, in the absence of p16INK4a, CDK6 can exert its full tumor-promoting function by enhancing proliferation and stimulating angiogenesis. The finding that CDK6 connects cell-cycle progression to angiogenesis confirms CDK6's central role in hematopoietic malignancies and could underlie the selection pressure to upregulate CDK6 and silence p16INK4a.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“On the other hand, CDK6-specific functions include participating as part of a transcription complex that regulates expression of p16INK4a and VEGF-A[5]”
From Development of dual and selective degraders of cyclin-dependent kinases 4 and 6 (2019) · cites this paper as [5]
In the citing paper
“Moreover, ATP-competitive inhibitors cannot disrupt the scaffolding functions of CDK6, which is important for the transcription function of CDK6 [124, 125].”
From Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies (2020) · cites this paper as [124]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Oncogenic activity of Cdc6 through repression of the INK4/ARF locus
González, S., Klatt, P., Delgado, S., Conde, E., López‐Ríos, F., Sánchez‐Céspedes, M., Méndez, J., Antequera, F., & Serrano, M. (2006) · Nature · doi:10.1038/nature04585 · Cited by 186
RetractedCDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
The Biology of Vascular Endothelial Growth Factor
Ferrara, N., & Davis-Smyth, T. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.1.0287 · Cited by 4,585
Vascular endothelial growth factor (VEGF) and its receptors
Neufeld, G., Cohen, T., Gengrinovitch, S., & Gluzman‐Poltorak, Z. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.1.9 · Cited by 3,511
Aging, Cellular Senescence, and Cancer
Campisi, J. (2013) · Annual Review of Physiology · doi:10.1146/annurev-physiol-030212-183653 · Cited by 2,954 · cited 1×
“Although p16 is also able to promote oncogene-induced senescence (Campisi, 2012), we failed to obtain any evidence of senescence.”
BackgroundRAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement
Shinkai, Y. (1992) · Cell · doi:10.1016/0092-8674(92)90029-c · Cited by 2,711
Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers
Nobori, T., Miura, K., Wu, D. J., Lois, A., Takabayashi, K., & Carson, D. A. (1994) · Nature · doi:10.1038/368753a0 · Cited by 1,742
Role of the INK4a Locus in Tumor Suppression and Cell Mortality
Serrano, M., Lee, H.-W., Chin, L., Cordon-Cardo, C., Beach, D., & DePinho, R. A. (1996) · Cell · doi:10.1016/s0092-8674(00)81079-x · Cited by 1,585
To cycle or not to cycle: a critical decision in cancer
Malumbres, M., & Barbacid, M. (2001) · Nature reviews. Cancer · doi:10.1038/35106065 · Cited by 1,510
Self-citationCyclin D as a therapeutic target in cancer
Musgrove, E. A., Caldon, C. E., Barraclough, J., Stone, A., & Sutherland, R. L. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3090 · Cited by 1,370
Flagged first, then by citations
3 of the 81 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Cell cycle proteins as promising targets in cancer therapy
Otto, T., & Siciński, P. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2016.138 · Cited by 1,931
Malumbres, M. (2014) · Genome biology · doi:10.1186/gb4184 · Cited by 1,730
Self-citationCDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
Deng, J., Wang, E. S., Jenkins, R. W., Li, S., Dries, R., Yates, K., Chhabra, S., Huang, W., Liu, H., Aref, A. R., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0915 · Cited by 770
“The digested NFATc3 and His-GB1 were separated and further purified using size exclusion chromatography (GE Healthcare Life Sciences “Superdex 75 10/300 GL”).”
BackgroundInfluentialTargeting cell-cycle machinery in cancer
Suski, J. M., Braun, M., Strmiska, V., & Siciński, P. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.03.010 · Cited by 587
Non-canonical functions of cell cycle cyclins and cyclin-dependent kinases
Hydbring, P., Malumbres, M., & Sicinski, P. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.27 · Cited by 528
Self-citationMechanisms of Sensitivity and Resistance to CDK4/6 Inhibition
Álvarez‐Fernández, M., & Malumbres, M. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.010 · Cited by 399
Self-citationcircRNA_100290 plays a role in oral cancer by functioning as a sponge of the miR-29 family
Chen, L., Zhang, S., Wu, J., Cui, J., Zhong, L., Zeng, L., & Ge, S. (2017) · Oncogene · doi:10.1038/onc.2017.89 · Cited by 391
RetractedCell cycle on the crossroad of tumorigenesis and cancer therapy
Liu, J., Peng, Y., & Wei, W. (2021) · Trends in Cell Biology · doi:10.1016/j.tcb.2021.07.001 · Cited by 394
Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review
Pandey, K., An, H. J., Kim, S., Lee, S. A., Kim, S., Lim, S. M., Kim, G. M., Sohn, J., & Moon, Y. W. (2018) · International Journal of Cancer · doi:10.1002/ijc.32020 · Cited by 376
Signaling Pathways in Cancer: Therapeutic Targets, Combinatorial Treatments, and New Developments
Yip, H. Y. K., & Papa, A. (2021) · Cells · doi:10.3390/cells10030659 · Cited by 341
Cyclin-dependent protein kinases and cell cycle regulation in biology and disease
Pellarin, I., Dall’Acqua, A., Favero, A., Segatto, I., Rossi, V., Crestan, N., Karimbayli, J., Belletti, B., & Baldassarre, G. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02080-z · Cited by 381
Aurora‐A Kinase: A Potent Oncogene and Target for Cancer Therapy
Yan, M., Wang, C., He, B., Yang, M., Tong, M., Long, Z., Liu, B., Peng, F., Xu, L., Zhang, Y., et al. (2016) · Medicinal Research Reviews · doi:10.1002/med.21399 · Cited by 296
CDK6 as a key regulator of hematopoietic and leukemic stem cell activation
Scheicher, R., Hoelbl‐Kovacic, A., Bellutti, F., Tigan, A.-S., Prchal‐Murphy, M., Heller, G., Schneckenleithner, C., Salazar‐Roa, M., Zöchbauer‐Müller, S., Zuber, J. A., et al. (2014) · Blood · doi:10.1182/blood-2014-06-584417 · Cited by 265
Self-citationDevelopment of dual and selective degraders of cyclin-dependent kinases 4 and 6
Jiang, B., Wang, E. S., Donovan, K. A., Liang, Y., Fischer, E. S., Zhang, T., & Gray, N. S. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201901336 · Cited by 272
Homolog-Selective Degradation as a Strategy to Probe the Function of CDK6 in AML
Brand, M., Jiang, B., Bauer, S., Donovan, K. A., Liang, Y., Wang, E. S., Nowak, R. P., Yuan, J. C., Zhang, T., Kwiatkowski, N., et al. (2019) · Cell Chemical Biology · doi:10.1016/j.chembiol.2018.11.006 · Cited by 258
Cyclin D-CDK4/6 functions in cancer
Gao, X., Leone, G. W., & Wang, H. (2020) · Advances in cancer research · doi:10.1016/bs.acr.2020.02.002 · Cited by 226
FLT3 Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging Controversies
Kennedy, V. E., & Smith, C. C. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.612880 · Cited by 206
Tigan, A.-S., Bellutti, F., Kollmann, K., Tebb, G., & Sexl, V (2016) · Oncogene · doi:10.1038/onc.2015.407 · Cited by 204
Self-citationRethink of EGFR in Cancer With Its Kinase Independent Function on Board
Thomas, R., & Weihua, Z. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00800 · Cited by 215
Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015–2019)
Sánchez-Martínez, C., Lallena, M. J., Sanfeliciano, S. G., & de Dios, A. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.126637 · Cited by 204
Nebenfuehr, S., Kollmann, K., & Sexl, V. (2020) · International Journal of Cancer · doi:10.1002/ijc.33054 · Cited by 187
Self-citationStructural Basis for the Non-catalytic Functions of Protein Kinases
Kung, J. E., & Jura, N. (2016) · Structure · doi:10.1016/j.str.2015.10.020 · Cited by 180
Requirement for CDK6 in MLL-rearranged acute myeloid leukemia
Placke, T., Faber, K., Nonami, A., Putwain, S. L., Salih, H. R., Heidel, F. H., Krämer, A., Root, D. E., Barbie, D. A., Krivtsov, A. V., et al. (2014) · Blood · doi:10.1182/blood-2014-02-558114 · Cited by 170
Immunomodulation by anticancer cell cycle inhibitors
Petroni, G., Formenti, S. C., Chen-Kiang, S., & Galluzzi, L. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0300-y · Cited by 163
INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors
Li, Q., Jiang, B., Guo, J., Shao, H., Priore, I. S. D., Chang, Q., Kudo, R., Li, Z., Razavi, P., Liu, B., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1726 · Cited by 169
Targeting CDK6 in cancer: State of the art and new insights
Tadesse, S., Yu, M., Kumarasiri, M., Le, B. T., & Wang, S. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1084445 · Cited by 168
Targeted protein degradation: current and future challenges
Hanzl, A., & Winter, G. E. (2020) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2019.11.012 · Cited by 157
Senescence as a therapeutically relevant response to CDK4/6 inhibitors
Wagner, V., & Gil, J. (2020) · Oncogene · doi:10.1038/s41388-020-1354-9 · Cited by 148
CK1α suppresses lung tumour growth by stabilizing PTEN and inducing autophagy
Cai, J., Li, R., Xu, X., Zhang, L., Lian, R., Fang, L., Huang, Y., Feng, X., Liu, X., Xu, L., et al. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0065-8 · Cited by 146
Cyclin-Dependent Kinase 6 Is a Chromatin-Bound Cofactor for NF-κB-Dependent Gene Expression
Handschick, K., Beuerlein, K., Jurida, L., Bartkuhn, M., Müller, H., Soelch, J., Weber, A., Dittrich-Breiholz, O., Schneider, H., Scharfe, M., et al. (2014) · Molecular Cell · doi:10.1016/j.molcel.2013.12.002 · Cited by 141
Steinebach, C., Ng, Y. L. D., Sosič, I., Lee, C.-S., Chen, S., Lindner, S., Vu, L. P., Bricelj, A., Haschemi, R., Monschke, M., et al. (2020) · Chemical Science · doi:10.1039/d0sc00167h · Cited by 148
Uras, I. Z., Walter, G. J., Scheicher, R., Bellutti, F., Prchal‐Murphy, M., Tigan, A.-S., Valent, P., Heidel, F. H., Kubicek, S., Scholl, C., et al. (2016) · Blood · doi:10.1182/blood-2015-11-683581 · Cited by 138
Self-citationCDK4/6 inhibitor resistance mechanisms and treatment strategies (Review)
Huang, J., Zheng, L., Sun, Z., & Li, J. (2022) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2022.5184 · Cited by 147
The Role of CDK4/6 Inhibition in Breast Cancer
Murphy, C. G., & Dickler, M. N. (2015) · The Oncologist · doi:10.1634/theoncologist.2014-0443 · Cited by 142
Selective degradation of CDK6 by a palbociclib based PROTAC
Rana, S., Bendjennat, M., Kour, S., King, H. M., Kizhake, S., Zahid, M., & Natarajan, A. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.03.035 · Cited by 135
Acquired resistance in cancer: towards targeted therapeutic strategies
Soragni, A., Knudsen, E. S., O’Connor, T. N., Tognon, C. E., Tyner, J. W., Gini, B., Kim, D., Bivona, T. G., Zang, X., Witkiewicz, A. K., et al. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00824-9 · Cited by 151
Palbociclib (PD0332991)—a Selective and Potent Cyclin-Dependent Kinase Inhibitor
Clark, A. S., Karasic, T. B., DeMichele, A. M., Vaughn, D. J., O’Hara, M. H., Perini, R. F., Zhang, P. J., Lal, P., Feldman, M. D., Gallagher, M., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.4701 · Cited by 132
Witkiewicz, A. K., & Knudsen, E. S. (2014) · Breast Cancer Research · doi:10.1186/bcr3652 · Cited by 129
Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
He, Y., Khan, S., Huo, Z., Lv, D., Zhang, X., Liu, X., Yuan, Y., Hromas, R., Xu, M., Zheng, G., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00924-z · Cited by 126
Adkins, D. R., Ley, J. C., Neupane, P. C., Worden, F. P., Sacco, A. G., Palka, K. A., Grilley‐Olson, J. E., Maggiore, R. J., Salama, N. N., Trinkaus, K. M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30405-x · Cited by 122
Targeting cell cycle regulators in hematologic malignancies
Aleem, E. A., & Arceci, R. J. (2015) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2015.00016 · Cited by 128
Transcriptomic characterization of fibrolamellar hepatocellular carcinoma
Simon, E. P., Freije, C. A., Farber, B. A., Lalazar, G., Darcy, D. G., Honeyman, J. N., Chiaroni-Clarke, R. C., Dill, B. D., Molina, H., Bhanot, U. K., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1424894112 · Cited by 115
Chou, A. S. Y., Froio, D., Nagrial, A. M., Parkin, A., Murphy, K. J., Chin, V. T., Wohl, D., Steinmann, A. M., Stark, R., Drury, A., et al. (2017) · Gut · doi:10.1136/gutjnl-2017-315144 · Cited by 121
Poratti, M., & Marzaro, G. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.03.064 · Cited by 117
Targeting the BRD4/FOXO3a/CDK6 axis sensitizes AKT inhibition in luminal breast cancer
Liu, J., Duan, Z., Guo, W., Zeng, L., Wu, Y., Chen, Y., Tai, F., Wang, Y., Lin, Y., Zhang, Q., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07258-y · Cited by 103
Cyclin-Dependent Kinases as Coregulators of Inflammatory Gene Expression
Schmitz, M. L., & Kracht, M. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.10.004 · Cited by 94
De Dominici, M., Porazzi, P., Xiao, Y., Chao, A., Tang, H.-Y., Kumar, G., Fortina, P., Spinelli, O., Rambaldi, A., Peterson, L. F., et al. (2020) · Blood · doi:10.1182/blood.2019003604 · Cited by 94
Crossing the LINE Toward Genomic Instability: LINE-1 Retrotransposition in Cancer
Kemp, J. R., & Longworth, M. S. (2015) · Frontiers in Chemistry · doi:10.3389/fchem.2015.00068 · Cited by 92
CDK4: a master regulator of the cell cycle and its role in cancer
Baker, S. J., Poulikakos, P. I., Irie, H. Y., Parekh, S. S., & Reddy, E. P. (2022) · Genes & Cancer · doi:10.18632/genesandcancer.221 · Cited by 84
CDK6 protects epithelial ovarian cancer from platinum‐induced death via FOXO3 regulation
Dall’Acqua, A., Sonego, M., Pellizzari, I., Pellarin, I., Canzonieri, V., D’Andrea, S., Benevol, S., Sorio, R., Giorda, G., Califano, D., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201607012 · Cited by 79
Cho, W. C., Jour, G., & Aung, P. P. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.06.015 · Cited by 83
Recent Advances in PROTACs for Drug Targeted Protein Research
Yao, T., Xiao, H., Wang, H., & Xu, X. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810328 · Cited by 79
CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety
Palmer, C. L., Boras, B. W., Pascual, B., Li, N., Li, D., Garza, S. J., Huser, N. H., Yuan, J. T., Cianfrogna, J. A., Sung, T., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.02.006 · Cited by 79
CDK6 Antagonizes p53-Induced Responses during Tumorigenesis
Bellutti, F., Tigan, A.-S., Nebenfuehr, S., Dolezal, M., Zojer, M., Grausenburger, R., Hartenberger, S., Kollmann, S., Doma, E., Prchal‐Murphy, M., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0912 · Cited by 75
Self-citationNK cells in hypoxic skin mediate a trade-off between wound healing and antibacterial defence
Sobecki, M., Krzywińska, E., Nagarajan, S., Audigé, A., Huỳnh, K., Zacharjasz, J., Debbache, J., Kerdiles, Y. M., Gotthardt, D., Takeda, N., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25065-w · Cited by 74
Self-citationCDK6 is an essential direct target of NUP98 fusion proteins in acute myeloid leukemia
Schmoellerl, J., Barbosa, I. A. M., Eder, T., Brandstoetter, T., Schmidt, L., Maurer, B., Troester, S., Pham, H. T. T., Mohanty, S., Ebner, J., et al. (2020) · Blood · doi:10.1182/blood.2019003267 · Cited by 74
Self-citationTherapeutic targeting of replicative immortality
Yaswen, P., MacKenzie, K. L., Keith, W. N., Hentosh, P., Rodier, F., Zhu, J., Firestone, G. L., Matheu, A., Carnero, A., Bilsland, A. E., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.03.007 · Cited by 82
Zhou, M., Zhou, L., Li, Z., Guo, L., Wang, Y., Liu, H., Ou, C., & Ding, Z. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100620 · Cited by 76
miR-582-5p inhibits proliferation of hepatocellular carcinoma by targeting CDK1 and AKT3
Zhang, Y., Huang, W. M., Ran, Y., Xiong, Y., Zhong, Z., Fan, X., Wang, Z., & Ye, Q. (2015) · Tumor Biology · doi:10.1007/s13277-015-3582-0 · Cited by 74
Chen, E. X., Hotte, S. J., Hirte, H. W., Siu, L. L., Lyons, J., Squires, M. S., Lovell, S., Turner, S., McIntosh, L., & Seymour, L. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.565 · Cited by 72
Fu, D., & Wang, T. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01485-7 · Cited by 70
Alves, C. L., Eliáš, D., Lyng, M., Bak, M., Kirkegaard, T., Lykkesfeldt, A. E., & Ditzel, H. J. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1984 · Cited by 68
Selective CDK6 degradation mediated by cereblon, VHL, and novel IAP-recruiting PROTACs
Anderson, N. A., Cryan, J., Ahmed, A., Dai, H., McGonagle, G. A., Rozier, C., & Benowitz, A. B. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127106 · Cited by 69
A kinase-independent role for CDK8 in BCR-ABL1+ leukemia
Menzl, I., Zhang, T., Berger‐Becvar, A., Grausenburger, R., Heller, G., Prchal‐Murphy, M., Edlinger, L., Knab, V. M., Uras, I. Z., Grundschober, E., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12656-x · Cited by 69
Self-citationNg, Y. L. D., Ramberger, E., Bohl, S., Dolnik, A., Steinebach, C., Conrad, T., Müller, S., Popp, O., Kull, M., Haji, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28515-1 · Cited by 68
CDK6 Inhibition: A Novel Approach in AML Management
Uras, I. Z., Sexl, V., & Kollmann, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072528 · Cited by 65
Self-citationKollmann, K., Warsch, W., Arias, C. G., Nice, F. L., Avezov, E., Milburn, J. V., Li, J., Dimitropoulou, D., Biddie, S. C., Wang, M., et al. (2016) · Leukemia · doi:10.1038/leu.2016.280 · Cited by 62
Self-citationCBX3 promotes colon cancer cell proliferation by CDK6 kinase-independent function during cell cycle
Fan, Y., Li, H., Liang, X., & Xiang, Z. (2017) · Oncotarget · doi:10.18632/oncotarget.15253 · Cited by 62
Exosomal miR-21-5p contributes to ovarian cancer progression by regulating CDK6
Cao, J., Zhang, Y., Mu, J., Yang, D., Gu, X., & Zhang, J. (2021) · Human Cell · doi:10.1007/s13577-021-00522-2 · Cited by 61
Functional genomics atlas of synovial fibroblasts defining rheumatoid arthritis heritability
Ge, X. J., Frank‐Bertoncelj, M., Klein, K., McGovern, A., Kuret, T., Houtman, M., Burja, B., Micheroli, R., Shi, C., Marks, M., et al. (2021) · Genome biology · doi:10.1186/s13059-021-02460-6 · Cited by 64
The CDK4/6-EZH2 pathway is a potential therapeutic target for psoriasis
Müller, A., Dickmanns, A., Resch, C., Schäkel, K., Hailfinger, S., Dobbelstein, M., Schulze‐Osthoff, K., & Kramer, D. (2020) · Journal of Clinical Investigation · doi:10.1172/jci134217 · Cited by 60
The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer
Shah, A. N., & Cristofanilli, M. (2017) · Current Treatment Options in Oncology · doi:10.1007/s11864-017-0443-7 · Cited by 62
Singh, L., Aldossary, S. A., Saeedan, A. S., Ansari, M. N., & Kaithwas, G. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.05.016 · Cited by 59
Leung, C. O. N., Yang, Y., Leung, R. W. H., So, K. K. H., Guo, H. J., Lei, M. M. L., Muliawan, G. K., Gao, Y., Yu, Q. Q., Yun, J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42360-w · Cited by 59
Human CDK18 promotes replication stress signaling and genome stability
Barone, G., Staples, C. J., Ganesh, A., Patterson, K. W., Bryne, D. P., Myers, K. N., Patil, A. A., Eyers, C. E., Maslen, S., Skehel, J. M., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw615 · Cited by 59
Progress with palbociclib in breast cancer: latest evidence and clinical considerations
Rocca, A., Schirone, A., Maltoni, R., Bravaccini, S., Cecconetto, L., Farolfi, A., Bronte, G., & Andreis, D. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834016677961 · Cited by 62
Biomedical application of Indole-3-carbinol: A mini-review
Singh, A. A., Patil, M. P., Kang, M., Niyonizigiye, I., & Kim, G. (2020) · Phytochemistry Letters · doi:10.1016/j.phytol.2020.09.024 · Cited by 56
The interplay of CDK4 and CDK6 in melanoma
Kollmann, K., Briand, C., Bellutti, F., Schicher, N., Blunder, S., Zojer, M., & Höeller, C. (2019) · Oncotarget · doi:10.18632/oncotarget.26515 · Cited by 56
Self-citationTargeting Protein Kinases Degradation by PROTACs
Yu, F., Cai, M., Shao, L., & Zhang, J. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.679120 · Cited by 55
Dai, M., Boudreault, J., Wang, N., Poulet, S., Daliah, G., Yan, G., Moamer, A., Burgos, S. A., Sabri, S., Ali, S., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-2121 · Cited by 54
Targeting the Non-Catalytic Functions: a New Paradigm for Kinase Drug Discovery?
Wang, Z., Huang, W., Zhou, K., Ren, X., & Ding, K. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01978 · Cited by 52
The application and research progress of anti-angiogenesis therapy in tumor immunotherapy
Tu, J., Liang, H., Li, C., Huang, Y., Wang, Z., Chen, X., & Yuan, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1198972 · Cited by 53
Yang, Q., Wang, P., Cui, J., Wang, W., Chen, Y., & Zhang, T. (2016) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2016.08.040 · Cited by 52
Kokuryo, T., Yokoyama, Y., Yamaguchi, J., Tsunoda, N., Ebata, T., & Nagino, M. (2019) · Anticancer Research · doi:10.21873/anticanres.13341 · Cited by 51
Zhang, J., Liu, X., Zhou, W., Cheng, G., Wu, J., Guo, S., Jia, S., Liu, Y., Li, B., Zhang, X., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-68224-7 · Cited by 51
miR-497 suppresses cycle progression through an axis involving CDK6 in ALK-positive cells
Hoareau‐Aveilla, C., Quelen, C., Congras, A., Caillet, N., Labourdette, D., Dozier, C., Brousset, P., Lamant, L., & Meggetto, F. (2018) · Haematologica · doi:10.3324/haematol.2018.195131 · Cited by 49
Ebron, J. S., Shankar, E., Singh, J., Sikand, K., Weyman, C. M., Gupta, S., Lindner, D. J., Liu, X., Campbell, M. J., & Shukla, G. C. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2993 · Cited by 49
H19 derived microRNA-675 regulates cell proliferation and migration through CDK6 in glioma.
Li, C., Lei, B., Huang, S., Zheng, M., Liu, Z., Li, Z., & Deng, Y. (2015) · Europe PMC (PubMed Central) · Cited by 48
CDK4/6 and MAPK—Crosstalk as Opportunity for Cancer Treatment
Scheiblecker, L., Kollmann, K., & Sexl, V. (2020) · Pharmaceuticals · doi:10.3390/ph13120418 · Cited by 48
Self-citationTargeting CDK4/6 for Anticancer Therapy
Qi, J., & Ouyang, Z. (2022) · Biomedicines · doi:10.3390/biomedicines10030685 · Cited by 49
Zhang, J., Zhou, L., Zhao, S., Dicker, D. T., & El‐Deiry, W. S. (2017) · Cell Cycle · doi:10.1080/15384101.2017.1320005 · Cited by 49
Palbociclib-mediated cell cycle arrest can occur in the absence of the CDK inhibitors p21 and p27
Pennycook, B. R., & Barr, A. R. (2021) · Open Biology · doi:10.1098/rsob.210125 · Cited by 45
Maurer, B., Brandstoetter, T., Kollmann, S., Sexl, V., & Prchal‐Murphy, M. (2020) · Haematologica · doi:10.3324/haematol.2020.256313 · Cited by 48
Self-citationmiR-124-3p is a chronic regulator of gene expression after brain injury
Vuokila, N., Łukasiuk, K., Bot, A. M., van Vliet, E. A., Aronica, E., Pitkänen, A., & Puhakka, N. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2911-z · Cited by 46
CDK6 coordinates JAK2V617F mutant MPN via NF-κB and apoptotic networks
Uras, I. Z., Maurer, B., Nivarthi, H., Jodl, P., Kollmann, K., Prchal‐Murphy, M., Feenstra, J. D. M., Zojer, M., Lagger, S., Grausenburger, R., et al. (2019) · Blood · doi:10.1182/blood-2018-08-872648 · Cited by 46
Self-citationAbdelmalak, M., Singh, R., Anwer, M. I., Ivanchenko, P., Randhawa, A., Ahmed, M., Ashton, A. W., Du, Y., Jiao, X., & Pestell, R. G. (2022) · Cancers · doi:10.3390/cancers14215388 · Cited by 45
Cyclin‐dependent kinases: Masters of the eukaryotic universe
Pluta, A. J., Studniarek, C., Murphy, S., & Norbury, C. J. (2023) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1816 · Cited by 45
Mazzoccoli, L., Robaina, M. C., Apa, A. G., Bonamino, M., Pinto, L. W., Queiroga, E., Bacchi, C. E., & Klumb, C. E. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-017-2575-3 · Cited by 45
Mechanisms of resistance to cyclin-dependent kinase 4/6 inhibitors
Gomatou, G., Trontzas, I. P., Ioannou, S., Drizou, M., Syrigos, N. K., & Kotteas, E. A. (2021) · Molecular Biology Reports · doi:10.1007/s11033-020-06100-3 · Cited by 45
Development of CDK4/6 Inhibitors: A Five Years Update
Ammazzalorso, A., Agamennone, M., Filippis, B. D., & Fantacuzzi, M. (2021) · Molecules · doi:10.3390/molecules26051488 · Cited by 48
Metadata
- Authors
- Kollmann, K., Heller, G., Schneckenleithner, C., Warsch, W., Scheicher, R., Ott, R. G., Schäfer, M., Fajmann, S., Schlederer, M., Schiefer, A.-I., Reichart, U., Mayerhofer, M., Hoeller, C., Zöchbauer-Müller, S., Kerjaschki, D., Bock, C., Kenner, L., Hoefler, G., Freissmuth, M., Green, A. R., Moriggl, R., Busslinger, M., Malumbres, M., & Sexl, V.
- Affiliations
- University of Veterinary Medicine Vienna (AT)
- Comprehensive Cancer Center Vienna (AT)
- Research Institute of Molecular Pathology (AT)
- Medical University of Vienna (AT)
- Austrian Academy of Sciences (AT)
- Ludwig Boltzmann Institute for Cancer Research (AT)
- Wellcome/MRC Cambridge Stem Cell Institute (GB)
- Spanish National Cancer Research Centre (ES)
- Corresponding author
- Sexl, Veronika
- ORCID
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2013-08
- Volume
- 24
- Issue
- 2
- Pages
- 167-181
- ISSN
- 1535-6108 (ISSN-L)
- PMC
- PMC5637299
- OpenAlex
- W2152600133
- Cited by
- 313
- References
- 81
- Citations by year
- 2026: 16 · 2025: 22 · 2024: 27 · 2023: 23 · 2022: 35 · 2021: 33 · 2020: 42 · 2019: 25 · 2018: 20 · 2017: 20 · 2016: 17 · 2015: 19 · 2014: 10 · 2013: 4
- FWCI
- 8.93
- Type
- journal article
- Language
- en
- Update notices
- erratum (2016-08-08)
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Cancer Cell (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust (079249, 100140)
- Medizinische Universität Wien
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Keywords
- CDK6, CDK4, p16INK4a, VEGF-A, tumor angiogenesis, B-cell acute lymphoblastic leukemia, BCR-ABL, transcriptional regulation, cell cycle, kinase-independent function, lymphoid malignancies, cell proliferation, hematologic malignancies
- MeSH terms
- Animals, Cell Cycle, Humans, Mice, Inbred C57BL, Mice, Nude, Mice, Transgenic, Neoplasms, Neovascularization, Pathologic, Leukemia, B-Cell, Lymphoma, B-Cell, Cyclin-Dependent Kinase 6, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
